ClouDr Group Limited (HK:9955)
:9955
Top Page
ClouDr Group Limited
(9955)
Select Model
Select Model
Rating:40Underperform
Price Target:
HK$0.87
▼(-12.60% Downside)
Action:ReiteratedDate:11/05/25
The overall stock score is primarily impacted by the company's financial performance challenges, including persistent net losses and reliance on external financing. Technical analysis indicates a bearish trend with oversold conditions, while valuation metrics reflect ongoing profitability issues. The lack of earnings call data and corporate events means these factors do not influence the score.
Positive Factors
Defensive retail pharmacy model
A retail pharmacy business centered on prescriptions and OTC products benefits from recurring, non-discretionary demand and an essential-healthcare positioning. This provides durable revenue stability and resilience across economic cycles, supporting steady cash flow potential over months.
Negative Factors
Persistent net losses
Ongoing and growing net losses erode retained earnings and limit reinvestment capacity. Persistent unprofitability forces dependence on external funding, constrains strategic initiatives, and raises execution risk on any multi-quarter recovery plan.
Read all positive and negative factors
Positive Factors
Negative Factors
Defensive retail pharmacy model
A retail pharmacy business centered on prescriptions and OTC products benefits from recurring, non-discretionary demand and an essential-healthcare positioning. This provides durable revenue stability and resilience across economic cycles, supporting steady cash flow potential over months.
Read all positive factors
ClouDr Group Limited (9955) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$463.27M
Dividend YieldN/A
Average Volume (3M)1.09M
Price to Earnings (P/E)―
Beta (1Y)2.06
Revenue Growth-43.86%
EPS Growth-217.25%
CountryHK
Employees1,218
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)-0.64
Shares Outstanding645,718,800
10 Day Avg. Volume899,970
30 Day Avg. Volume1,090,236
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)0.45
Price to Sales (P/S)0.19
P/FCF Ratio-2.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.11
Revenue Forecast (FY)HK$7.73B
ClouDr Group Limited Business Overview & Revenue Model
Company Description
ClouDr Group Limited, an investment holding company, provides supplies and software as a service (SaaS) to hospitals and pharmacies, digital marketing services to pharmaceutical companies, and online consultation and prescriptions for chronic cond...
How the Company Makes Money
ClouDr Group Limited generates revenue through multiple key streams, including subscription fees for its software-as-a-service (SaaS) products, which provide clients with access to cloud-based applications and services on a recurring basis. Additi...
ClouDr Group Limited Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
40
Negative
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.26B | 3.49B | 3.69B | 2.99B | 1.76B | 839.12M |
| Gross Profit | 755.69M | 861.67M | 909.38M | 792.10M | 570.02M | 232.76M |
| EBITDA | -764.00M | -372.34M | -208.37M | -1.58B | -4.06B | -2.86B |
| Net Income | -949.68M | -516.41M | -323.06M | -1.69B | -4.14B | -2.87B |
Balance Sheet | ||||||
| Total Assets | 2.15B | 2.84B | 2.95B | 2.83B | 2.51B | 1.69B |
| Cash, Cash Equivalents and Short-Term Investments | 445.29M | 525.84M | 595.10M | 723.17M | 1.12B | 981.42M |
| Total Debt | 558.23M | 581.24M | 469.69M | 228.67M | 9.03B | 358.62M |
| Total Liabilities | 1.33B | 1.41B | 1.18B | 953.05M | 9.66B | 5.08B |
| Stockholders Equity | 962.37M | 1.45B | 1.83B | 1.85B | -7.14B | -3.36B |
Cash Flow | ||||||
| Free Cash Flow | -24.36M | -225.19M | -263.46M | -809.87M | -755.02M | -478.99M |
| Operating Cash Flow | 61.47M | -148.39M | -140.43M | -642.63M | -666.33M | -438.46M |
| Investing Cash Flow | 40.20M | 66.87M | -38.34M | -744.94M | -155.50M | -160.20M |
| Financing Cash Flow | 7.56M | 147.99M | 171.81M | 503.55M | 1.02B | 918.41M |
ClouDr Group Limited Technical Analysis
Neutral
1.00
Price Trends
0.79
Negative
0.92
Negative
1.14
Negative
Market Momentum
-0.02
Negative
52.51
Neutral
87.30
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9955, the sentiment is Neutral. The current price of 1 is above the 20-day moving average (MA) of 0.66, above the 50-day MA of 0.79, and below the 200-day MA of 1.14, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 52.51 is Neutral, neither overbought nor oversold. The STOCH value of 87.30 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:9955.
ClouDr Group Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | HK$6.36B | 19.61 | 6.83% | 2.72% | 29.81% | 10.40% | |
66 Neutral | HK$1.82B | 20.84 | 4.85% | 3.81% | 0.33% | -44.28% | |
60 Neutral | HK$627.48M | 7.99 | 7.98% | 8.03% | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
40 Underperform | HK$463.27M | -0.61 | -66.54% | ― | -43.86% | -217.25% |
* Healthcare Sector Average
HK:9955
ClouDr Group Limited
0.72
-0.25
-25.77%
HK:1931
IVD Medical Holding Limited
1.12
-0.58
-34.12%
HK:2192
Medlive Technology Co., Ltd.
8.61
-0.89
-9.37%
HK:2289
Charmacy Pharmaceutical Co., Ltd. Class H
5.81
-1.31
-18.40%
ClouDr Group Limited Corporate Events
ClouDr Group Names HR Chief Hu Yue as Executive Director and Nomination Committee Member
Dec 28, 2025
ClouDr Group Limited has appointed Hu Yue, the group’s long-serving vice president and head of human resources, as an executive director and member of its nomination committee, effective 27 December 2025. Hu, a seasoned HR executive with pri...
ClouDr Group Sets Out Board and Committee Structure
Dec 28, 2025
ClouDr Group Limited announced the current composition of its board of directors, comprising executive directors Kuang Ming, who serves as chairman and chief executive officer, and Hu Yue, alongside independent non-executive directors Hong Weili, ...
ClouDr Group Partners with JD Health to Enhance Online Healthcare Services
Nov 13, 2025
ClouDr Group Limited has entered a service cooperation agreement with JD Health to expand online sales and service channels for its products, including Remifemin. This collaboration leverages JD Health’s extensive platform resources and Clou...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.